This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Swiryn, S. Articles by Rosen, K. M. Search for Related Content PubMed PubMed Citation Articles by Swiryn, S. Articles by Rosen, K. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Circulation, Vol 64, 169-175, Copyright © 1981 by American Heart Association

ARTICLES

Effects of oral disopyramide phosphate on induction of paroxysmal supraventricular tachycardia

S Swiryn, RA Bauernfeind, CR Wyndham, RC Dhingra, E Palileo, B Strasberg and KM Rosen

The effects of oral disopyramide phosphate on laboratory induction of paroxysmal supraventricular tachycardia (PSVT) were studied in 16 patients with clinical PSVT. After control electrophysiologic study to determine the inducibility and mechanism of PSVT, patients were given 200-300 mg (275 +/- 45 mg, mean +/- SD) of disopyramide for three to five doses over 24 hours and were then restudied. All patients had inducible, sustained PSVT during the control study. After disopyramide, PSVT was noninducible in eight patients (50%), including six of nine with atrioventricular nodal reentrance and two of seven with atrioventricular reentrance; inducible but nonsustained in two (12.5%) (both with atrioventricular reentrance); and inducible and sustained in six (37.5%). The benefit of disopyramide seemed predominantly to reflect depression of conduction in the retrograde limb of the circus movements, although effects upon the antegrade limb were also observed. In the eight patients with inducible PSVT before and after disopyramide, tachycardia cycle length increased from 348 +/- 33 to 404 +/- 29 msec (mean +/- SEM) (p less than 0.001). These results suggest that disopyramide would be effective in preventing recurrence of clinical PSVT in selected patients.

This article has been cited by other articles:

				R. R. Wilson and A. G. Wallace Disopyramide: Six Years' Experience Angiology, June 1, 1983; 34(6): 367 - 374. [Abstract] [PDF]